86 results about "Corneal Injury" patented technology

The invention discloses a tissue engineering cornea epithelial transplantation membrane, a preparing method and an application thereof. The invention aims to provide a tissue engineering cornea epithelial transplantation membrane, the tissue engineering cornea epithelial transplantation membrane comprises a porcine cornea epithelial cell and nonantigenic tissue engineering cornea bracket material, wherein, the porcine cornea epithelial cell and the nonantigenic tissue engineering cornea bracket material are combined into a whole by adopting a tissue engineering method. And meanwhile, The invention further provides a method for preparing the tissue engineering cornea epithelial transplantation membrane, and a use of the tissue engineering cornea epithelial transplantation membrane during the process of preparing medical treatment material used for remedying blind eye disease caused by the pathological state and the damage of corneas.

Compositions including a quinolone component, such as ofloxacin, having fungistatic activity in the compositions, present in an amount effective as an antibiotic when the composition is placed in a mammalian eye, a NSAID component present in an amount to reduce inflammation or pain when the composition is placed in the eye, and a carrier component in an amount effective to act as a carrier for the quinolone component and NSAID component are provided. Methods of using the present compositions, for example, to resolve microbial infections and / or to reduce inflammation and / or pain in a mammalian eye are included within the scope of the present invention. Methods for treating corneal injuries are also included. In addition, methods for treating ocular infections, for example, corneal infections, are included.

The invention relates to a method for manufacturing and storing a corneal injury scar-free repairing device. Specially-prepared amnion elements are settled or bonded in or on the surfaces of various biological or synthetic attaching devices such as the invisible contact lens through the novel carrier controlled release technology and the biological tissue engineering technology so as to form the corneal or conjunctiva injury scar-free repairing device. At the early stage of the corneal or conjunctiva injury, the affected corneal tissue or the affected conjunctiva tissue is covered with the amnion elements of the corneal or conjunctiva injury scar-free repairing device, the amnion elements, such as the necessary cell growth factors, the tissue repair factors and protease inhibitors, of the corneal or conjunctiva injury scar-free repairing device are diffused to the affected corneal tissue or the affected conjunctiva tissue due to the special superfine structure of an amnion basilar membrane and the stem cell characteristic of amniotic epithelial cells, and therefore growth of epithelial cells of the corneal or the conjunctiva is promoted, the affected corneal tissue or the affected conjunctiva tissue is stimulated, regulated and controlled to heal orderly, and less scars are formed on the affected corneal tissue or the affected conjunctiva tissue.

The present invention provides methods of treating a subject suffering from adverse effects, complications or conditions, associated with or resulting from a corneal injury including, corneal infection or ulceration, by topical administration of suitable ophthalmic preparations of bactericidal / permeability-increasing (BPI) protein products.

In order to solve the problem of lack of specific medicines for corneal injury at present, the present invention provides the use of DNA tetrahedron in preparing a medicine for treating corneal injury, the DNA tetrahedron is a tetrahedral nanostructure formed by four DNA single strands through base complementary pairing . The invention can effectively promote tissue regeneration, realize the healing of damaged cornea, has no toxic and side effects, and has a simple preparation process.

The invention provides a corneal contact lens cleaning machine. The corneal contact lens cleaning machine aims to solve the problems that people need to pay attention to daily cleaning, sterilization,storage and other care work of corneal contact lenses, otherwise, corneal infection, keratitis and corneal injury are caused very easily; the lenses are difficult and complicated to clean; accordingto a traditional cleaning mode, the corneal contact lenses are rubbed with fingers, many people use improper cleaning methods, the lenses are not stressed evenly, nails are too long, cross contamination of the lenses is easily caused by bacteria left on the fingers and in the nails, the lenses are always scratched and damaged and severely abraded, and accordingly the lenses are not easy to clean or optical characteristics of the lenses are changed. Compared with the prior art, the corneal contact lens cleaning machine has the beneficial effects that the traditional manual cleaning mode of thecorneal contact lenses is changed, a cleaning brush is adopted for automatic cleaning and disinfection, the lenses are automatically sprayed and blown dry, finger contact is avoided in the whole process, abrasion of the lenses is reduced, and the lenses are cleaned better.

The invention relates to a novel thrombin fragment fusogenic peptide S-TP508 which is obtained by adding a section of stable peptide on the N end of TP508 (the section of stable peptide mainly comprises glutamine and arginine). The fusogenic peptide S-TP508 added with the stable peptide has prolonged half-life period compared with the TP508, overcomes the defect of easiness of enzymolysis of the TP508 and enhances the stability. The invention also relates to a medical composite containing the S-TP508 and application thereof to preparing drugs for treating skin tissue injury and corneal injury.

The invention relates to the technical field of stem cells, in particular to application of umbilical cord mesenchymal stem cells to preparation of a stem cell preparation for treating corneal injury. Studies show that the umbilical cord mesenchymal stem cells can promote the corneal epithelium healing; the cornea turbid degree is low; the generation of cornea blood vessels is reduced; the cornea epithelial tissue can be more effectively repaired; the umbilical cord mesenchymal stem cells can be used for treating cornea alkali burn. The stem cells in the preparation are from the umbilical cord; the collection is convenient and is noninvasive operation; the obtained mesenchymal stem cells are infantile than other mesenchymal stem cells; the multiplication and differentiative potential is great; the umbilical cord resource is rich, and the large-scale production can be realized; the ethic limitation is avoided; the immunogenicity is low; the wide application prospects are realized in the field of corneal injury treatment.

The invention relates to the field of biological medicine, particularly discloses actin binding peptide and the purpose of the actin binding peptide. The amino acid sequence of the actin binding peptide is LKKTETQ, the synthesis difficulty and the cost are lowered, the actin binding peptide is suitable for batch production in a large scale and has a brilliant preparing function on various corneal injuries, side effects do not appear in the dosing process, and corneal wound healing and transparency recovery are benefited. Compared with a curing method through thymosin beta4, the advantages are more obvious, the side effects are small, and the actin binding peptide can be used for corneal repairing treatment.

The invention discloses serum-free cultured corneal limbus stromal stem cells and a method for inducing differentiation and stem cell balling of the corneal limbus stromal stem cells. The invention further provides a culture medium combination for inducing corneal limbus stromal stem cells to be pelletized or differentiated into corneal limbus stromal cells in vitro. The serum-free culture mediumcombination used in the invention can provide sufficient nutrition and a good environment required by cell growth and proliferation, can stably carry out in-vitro amplification culture on corneal limbus stromal stem cells, and can ensure that the dryness and specificity of the corneal limbus stromal stem cells are still maintained after amplification culture. Meanwhile, a system for inducing and differentiating into corneal limbus stromal cells is successfully constructed, can be used for experimental research of the corneal limbus stromal stem cells, cell treatment of corneal lesions and transplantation of corneal injuries, and the serum-free cultured corneal limbus stromal stem cells has wide scientific benefits and social and economic benefits.

The invention provides an application of nicotinamide adenine dinucleotide or a precursor substance thereof in preparation of a medicament for treating corneal epithelial defect, and relates to the technical field of ophthalmic medicaments. Research shows that the expression of the nicotinamide phosphotransferase in epithelial cells after the corneal injury is abnormal, so that the level of the nicotinamide purine dinucleotide in the corneal epithelial cells is reduced, and the nicotinamide phosphodinucleotide can promote the repair of the corneal epithelial cells, therefore, applying the nicotinamide adenine dinucleotide or the precursor substance thereof to local area of an eye can effectively accelerate the repair of corneal epithelial cells and effectively treat corneal epithelial defects. According to the invention, the nicotinamide adenine dinucleotide or the precursor substance thereof is applied to the preparation of the medicament for treating corneal epithelial defect, and the medicament has wide development and application prospects.